Eli Lilly and Company $LLY Stock: Tamar Securities LLC Boosts Stake

Tamar Securities LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,808 shares of the company’s stock after buying an additional 447 shares during the quarter. Eli Lilly and Company comprises approximately 2.0% of Tamar Securities LLC’s holdings, making the stock its 24th largest position. Tamar Securities LLC’s holdings in Eli Lilly and Company were worth $21,763,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. OPTIMAS CAPITAL Ltd bought a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $1,641,000. Prudent Man Investment Management Inc. boosted its position in shares of Eli Lilly and Company by 18.3% during the 3rd quarter. Prudent Man Investment Management Inc. now owns 84 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares during the last quarter. May Hill Capital LLC boosted its position in shares of Eli Lilly and Company by 4.2% during the 3rd quarter. May Hill Capital LLC now owns 1,832 shares of the company’s stock valued at $2,120,000 after acquiring an additional 74 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 31.6% in the third quarter. Alps Advisors Inc. now owns 19,618 shares of the company’s stock valued at $22,700,000 after purchasing an additional 4,707 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC grew its holdings in shares of Eli Lilly and Company by 0.6% in the third quarter. Ashton Thomas Private Wealth LLC now owns 21,338 shares of the company’s stock valued at $24,690,000 after purchasing an additional 119 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LLY shares. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research report on Tuesday, September 15th. BMO Capital Markets reiterated an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Guggenheim boosted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,404.14.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $17,020,770 over the last three months. 0.14% of the stock is owned by company insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,372.15 on Friday. The firm has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 44.54, a PEG ratio of 1.69 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The business has a 50 day simple moving average of $1,215.24 and a 200-day simple moving average of $1,101.16. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $7.02 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.